Srinivasan G, Boschman C, Roth S I, Hendel R C
Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA.
Clin Cardiol. 1997 Jan;20(1):84-6. doi: 10.1002/clc.4960200118.
Treatment with thrombolytic agents such as streptokinase or tissue plasminogen activator (TPA) is an accepted standard for the treatment of patients with acute myocardial infarction (MI). A devastating sequel of thrombolytic therapy may be the development of a hemorrhagic complication, particularly intracranial bleeding, which, although rare, is usually associated with significant neurologic sequelae or death. While various risk factors have been correlated with the development of intracranial hemorrhage following thrombolysis, a possible relationship between bleeding and a clinically unsuspected underlying vasculitis has not been previously reported. This report deals with the case of a 49-year-old man who died of multiple intracranial hemorrhages after thrombolytic therapy for acute MI and who was found at autopsy to have had polyarteritis nodosa of the coronary arteries and vasculitis of the meningeal vessels.
使用链激酶或组织纤溶酶原激活剂(TPA)等溶栓剂治疗是急性心肌梗死(MI)患者治疗的公认标准。溶栓治疗的一个毁灭性后果可能是出血并发症的发生,尤其是颅内出血,虽然罕见,但通常会伴有严重的神经后遗症或死亡。虽然各种危险因素与溶栓后颅内出血的发生相关,但出血与临床上未被怀疑的潜在血管炎之间的可能关系此前尚未见报道。本报告涉及一名49岁男性的病例,该患者在接受急性心肌梗死溶栓治疗后死于多发性颅内出血,尸检发现其患有冠状动脉结节性多动脉炎和脑膜血管血管炎。